<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04371796</url>
  </required_header>
  <id_info>
    <org_study_id>EK2019001</org_study_id>
    <nct_id>NCT04371796</nct_id>
  </id_info>
  <brief_title>Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC</brief_title>
  <official_title>Exploratory Efficacy and Safety Study of PD-1 Inhibitor Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sichuan Cancer Hospital and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Innovent Biologics, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sichuan Cancer Hospital and Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study was to investigate the safety and efficacy of Sintilimab (IBI308) in
      patients with resectable NSCLC, and to provide new treatment options for neoadjuvant therapy
      in patients with stage II-IIIA NSCLC
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sintilimab injection (IBI308) as neoadjuvant therapy in patients with resectable NSCLC
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 10, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major pathologic response rate(MPR)(&lt;10% viable tumor cells)</measure>
    <time_frame>At time of surgery</time_frame>
    <description>To assess the major pathologic response rate (&lt;10% viable tumor cells) in patients receiving Sintilimab Injection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>the proportion of patients with a best overall response of CR, PR or SD in the whole body, as assessed per RECIST 1.1 by the investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>the proportion of patients with a best overall confirmed response of CR or PR in the whole body as assessed per RECIST 1.1 by the investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival (DFS)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Defined as the time from date of surgery until recurrence of tumor or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of irAEs</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Immune-related AE per Common Terminology Criteria for Adverse Events (CTCAE V5.0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of SAEs</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Grade 3 or higher per Common Terminology Criteria for Adverse Events (CTCAE V5.0)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Lung Diseases</condition>
  <condition>Neoplasms</condition>
  <condition>Respiratory Tract Diseases</condition>
  <condition>Thoracic Neoplasms</condition>
  <condition>Non-small-cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Sintilimab injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drugs: Eligible patients received two doses of intravenous sintilimab (200 mg) every 3 weeks (Q3W). Each infusion time is 30-60min.
Surgery: The patient underwent imaging examinations within 7 days prior to surgery, including chest CT and related metastatic examinations. The patient underwent surgery 6-8 weeks after the first dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sintilimab injection</intervention_name>
    <description>Sintilimab injection 200mg, 2cycles of treatment before surgery</description>
    <arm_group_label>Sintilimab injection</arm_group_label>
    <other_name>IBI308</other_name>
    <other_name>Xindili Dankang</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age: 18 years old to 75 years old, male or female;

          2. Histologically or cytologically confirmed NSCLC (stage II-IIIA, American Joint
             Committee on Cancer, eighth edition) that was surgically resectable;

          3. Being treatment-naive and the diameter of primary tumor was greater than or equal to 1
             cm;

          4. ECOG performance status score: 0-1;

          5. The function of important organs meets the following requirements (no blood components
             and cell growth factors are allowed for 2 weeks before the start of study): Absolute
             neutrophil count (ANC)≥1.5×10 E+9/L; platelets≥100×10E+9/L / L; hemoglobin ≥9g/dL;
             serum albumin(ALB)≥2.8g/dL; a total bilirubin (TBil) of≤1.5 ULN, ALT and AST≤2.5 ULN,
             in case of liver metastasis, ALT and AST≤5 ULN; creatinine clearance rate≥
             50mL/min(Cockcroft-Gault);thyroid function is normal.

          6. Estimated survival time≥3 months;

          7. PD-L1 expression level ≥ 1%；

          8. Patients were voluntarily enrolled in the study and signed an informed consent form
             (ICF) with good adherence and follow-up.

        Exclusion Criteria:

          1. The patient has any active autoimmune disease or a history of autoimmune disease;

          2. The patient is using immunosuppressive agents or systemic hormonal therapy for
             immunosuppression purposes (dose&gt;10 mg / day of prednisone or other therapeutic
             hormones);

          3. History of interstitial lung disease;

          4. Severe allergic reactions to other monoclonal antibodies;

          5. Previous allogeneic organ transplantation or hemopoietic stem cell transplantation;

          6. Have clinical symptoms or disease that are not well controlled ;

          7. Grade III to grade IV congestive heart failure;

          8. Uncontrolled hypertension;

          9. Artery thrombosis, embolism, or ischemia within 6 months before study treatment;

         10. Coagulation disorders;

         11. Active and uncontrolled infection;

         12. The patient has previously received other PD-1 antibody therapy or other immunotherapy
             against PD-1/PD-L1;

         13. Any other known malignant tumor;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan Li, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sichuan Cancer Hospital and Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Juan Li, MD</last_name>
    <phone>+8613880276636</phone>
    <email>dr.lijuan@gmail.com</email>
  </overall_contact>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 29, 2020</study_first_submitted>
  <study_first_submitted_qc>April 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2020</study_first_posted>
  <last_update_submitted>April 29, 2020</last_update_submitted>
  <last_update_submitted_qc>April 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sichuan Cancer Hospital and Research Institute</investigator_affiliation>
    <investigator_full_name>Juan LI, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <keyword>neoadjuvant</keyword>
  <keyword>Sintilimab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thoracic Neoplasms</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

